Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Selencin effectively reduces hair loss and improves hair health in diffuse alopecia.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.